Prudential Financial’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Prudential Financial’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,094	Closed	-$86K	–	2325
2015 Q1	$86K	Buy	1,094 +10	+0.9%	+$620	﹤0.01%	2191
2014 Q4	$66K	Buy	1,084 +10	+0.9%	+$502	﹤0.01%	2161
2014 Q3	$46K	Sell	1,074 -1,045	-49%	-$56.1K	﹤0.01%	2186
2014 Q2	$131K	Sell	2,119 -885	-29%	-$51.5K	﹤0.01%	2320
2014 Q1	$195K	Buy	3,004 +40	+1%	+$2.71K	﹤0.01%	2168
2013 Q4	$167K	Hold	2,964	–	–	﹤0.01%	2200
2013 Q3	$182K	Sell	2,964 -1,060	-26%	-$71.8K	﹤0.01%	2178
2013 Q2	$235K	Buy	+4,024	New	+$248K	﹤0.01%	2135

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Prudential Financial's OREX Position: Q2 2015 in Review

Prudential Financial sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 1,094 shares — an estimated $86K sold.

Prudential Financial first reported a position in OREX in Q2 2013 and held it in 8 quarters. The position peaked at $235K in Q2 2013. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

Prudential Financial reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Prudential Financial sold 1,094 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $86K.
Prudential Financial first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 8 quarters.
Prudential Financial's Orexigen Therapeutics, Inc. position peaked at $235K in Q2 2013.
161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Prudential Financial's 13F filing for Q2 2015, filed 6 Aug 2015.